Better Patient Care Through Innovation

 

Breaking News

INSYS is proud to announce the first and only liquid dronabinol, SYNDROS, has received approval from the FDA.

Read More

About INSYS

INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of patients' lives. Using proprietary sublingual spray technology and our capabilities to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing commercial products.

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

Recent News

Insys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy

Recent News

Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol

Recent News

Insys Therapeutics Reports Second Quarter 2016 Results

Recent News

Insys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy

Recent News

Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol

Recent News

Insys Therapeutics Reports Second Quarter 2016 Results